Private biotechnology company developing proprietary small-molecule therapies and diagnostic biomarkers for complex diseases, initially focused on CNS disorders
Private biotechnology company developing proprietary small-molecule therapies and diagnostic biomarkers for complex diseases, initially focused on CNS disorders. It uses knowledge mapping and mitochondrial expertise to identify targets at the intersection of genetic, mitochondrial, and environmental dysfunction. Its preclinical programs include Rett syndrome and Parkinson’s disease.